Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SenzaGen AB's Free Cash Flow for the
three
months ended in Mar. 2026 was €-0.42 Mil. SenzaGen AB's Revenue for the
three
months ended in Mar. 2026 was €1.39 Mil. Therefore, SenzaGen AB's FCF Margin % for the quarter that ended in Mar. 2026 was -30.45%.
The historical rank and industry rank for SenzaGen AB's FCF Margin % or its related term are showing as below:
FRA:26S'
s FCF Margin % Range Over the Past 10 Years
Min: -2797.19 Med: -276.6 Max: -19.08
Current: -25.31
During the past 11 years, the highest FCF Margin % of SenzaGen AB was -19.08%. The lowest was -2797.19%. And the median was -276.60%.
FRA:26S's FCF Margin % is ranked worse than 68.14% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.7
vs FRA:26S: -25.31
SenzaGen AB FCF Margin % Related Terms
SenzaGen AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:26S vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (FRA:26S) has a FCF Margin % of -30.45% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #139 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 68.1%.
Is SenzaGen AB's FCF Margin % too high?
SenzaGen AB's current FCF Margin % is -30.45%. Based on the distribution chart, SenzaGen AB ranks #139 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, SenzaGen AB has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #139 out of 204 companies for FCF Margin %. This places SenzaGen AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on SenzaGen AB and its competitors. SenzaGen AB's current FCF Margin % is -30.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
SenzaGen AB (FRA:26S) has a current FCF Margin % of -30.45%. The stock's GF Value™ is €0.57, compared to a current price of €0.47 — trading 17.2% below its estimated fair value. The current FCF Margin % is -30.45%. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For SenzaGen AB (FRA:26S), the current FCF Margin % is -30.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (FRA:26S) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of €0.47 is trading 17.2% below its estimated GF Value™ of €0.57.
Key valuation signals for FRA:26S:
FCF Margin %: -30.45%
GF Value™: €0.57 vs. price of €0.47 (17.2% below fair value)
No single metric tells the full story. See the FRA:26S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for FRA:26S
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:26S has been successfully added to your 
